MA49651A - Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte - Google Patents

Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte

Info

Publication number
MA49651A
MA49651A MA049651A MA49651A MA49651A MA 49651 A MA49651 A MA 49651A MA 049651 A MA049651 A MA 049651A MA 49651 A MA49651 A MA 49651A MA 49651 A MA49651 A MA 49651A
Authority
MA
Morocco
Prior art keywords
compositions
methods
diseases associated
treating diseases
impression
Prior art date
Application number
MA049651A
Other languages
English (en)
Inventor
Azusa Inoue
Yi Zhang
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of MA49651A publication Critical patent/MA49651A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y114/00Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA049651A 2017-07-19 2018-07-19 Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte MA49651A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762534532P 2017-07-19 2017-07-19

Publications (1)

Publication Number Publication Date
MA49651A true MA49651A (fr) 2021-04-28

Family

ID=65016147

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049651A MA49651A (fr) 2017-07-19 2018-07-19 Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte

Country Status (5)

Country Link
US (2) US12178854B2 (fr)
EP (1) EP3654956A4 (fr)
CN (1) CN111132671B (fr)
MA (1) MA49651A (fr)
WO (1) WO2019018635A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102473092B1 (ko) 2014-09-15 2022-12-01 칠드런'즈 메디컬 센터 코포레이션 히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
MA49651A (fr) 2017-07-19 2021-04-28 Childrens Medical Center Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte
US20210155959A1 (en) * 2018-04-06 2021-05-27 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
KR102732761B1 (ko) * 2018-07-19 2024-11-25 칠드런'즈 메디컬 센터 코포레이션 생리학적 x 염색체 불활성화를 생성하기 위한 조성물 및 방법
CN113801851B (zh) * 2020-06-17 2025-07-25 中国科学院动物研究所 一种体细胞核移植方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664097A (en) 1984-05-09 1987-05-12 The Wistar Institute Of Anatomy & Biology Nuclear transplantation in the mammalian embryo by microsurgery and cell fusion
US4994384A (en) 1986-12-31 1991-02-19 W. R. Grace & Co.-Conn. Multiplying bovine embryos
US5057420A (en) 1987-06-05 1991-10-15 Granada Biosciences, Inc. Bovine nuclear transplantation
US6107543A (en) 1992-08-20 2000-08-22 Infigen, Inc. Culture of totipotent embryonic inner cells mass cells and production of bovine animals
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB2331751B (en) 1995-08-31 2000-01-19 Roslin Inst Quiescent cell populations for nuclear transfer
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US6700037B2 (en) 1998-11-24 2004-03-02 Infigen, Inc. Method of cloning porcine animals
CN1242061C (zh) 2001-01-04 2006-02-15 上海交通大学 一种短指基因
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
AU2012253359B2 (en) 2011-05-11 2017-06-08 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
CA2887243C (fr) 2012-10-15 2024-04-09 Epizyme, Inc. Methodes de traitement du cancer
WO2015048577A2 (fr) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Compositions et méthodes relatives aux répétitions palindromiques groupées, courtes et régulièrement espacées
KR20210117347A (ko) 2013-12-06 2021-09-28 에피자임, 인코포레이티드 암 치료를 위한 병용 요법
EP3111222A1 (fr) * 2014-02-26 2017-01-04 Glaxosmithkline Intellectual Property (No. 2) Limited Méthodes de traitement de patients atteints de cancer réagissant à l'inhibiteur d'ezh2 gsk126
MX394629B (es) 2014-10-16 2025-03-24 Epizyme Inc Método para tratar el cáncer.
EP4309738A3 (fr) 2015-10-06 2024-07-17 Epizyme, Inc. Procédé de traitement du médulloblastome avec un inhibiteur d'ezh2
WO2017079738A1 (fr) 2015-11-05 2017-05-11 Epizyme, Inc. Cytométrie de flux permettant de surveiller l'état de la méthylation d'une histone h3
EP3386513A2 (fr) 2015-12-07 2018-10-17 Epizyme Inc Inhibiteurs d'ezh2 et leur utilisation
MA49651A (fr) 2017-07-19 2021-04-28 Childrens Medical Center Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte

Also Published As

Publication number Publication date
WO2019018635A1 (fr) 2019-01-24
CN111132671A (zh) 2020-05-08
EP3654956A4 (fr) 2021-04-28
US20200179491A1 (en) 2020-06-11
US20240000900A1 (en) 2024-01-04
CN111132671B (zh) 2023-10-27
EP3654956A1 (fr) 2020-05-27
US12178854B2 (en) 2024-12-31

Similar Documents

Publication Publication Date Title
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
EP3890748A4 (fr) Compositions et procédés de traitement de troubles hépatiques
EP3869985A4 (fr) Composition et méthode pour traiter les poumons
EP3496739A4 (fr) Compositions et procédés de traitement de l'hypertension pulmonaire
EP3319976A4 (fr) Compositions et procédés pour traiter des maladies pulmonaires et des lésions pulmonaires
EP3701041A4 (fr) Méthodes et compositions pour traiter des maladies associées à des lymphocytes t épuisés
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
MA49651A (fr) Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte
EP3612215A4 (fr) Compositions et procédés pour le traitement d'inflammation pulmonaire
EP3615016A4 (fr) Procédés et compositions pour le traitement d'apnée du sommeil
EP3273944A4 (fr) Compositions et procédés permettant d'administrer des agents de type biomacromolécule
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA52134A (fr) Compositions et procédés pour l'édition génomique
EP3331542A4 (fr) Compositions et procédés pour traiter des cancers associés à l'activation d'etbr
IL277182A (en) Compositions and methods for treating Parkinson's disease
EP3973047A4 (fr) Procédés et compositions pour le traitement de troubles hépatiques
EP3488018A4 (fr) Procédés et compositions pour l'identification de protéines
EP3701048A4 (fr) Procédés et compositions pour évaluer et traiter des maladies et des troubles intraoculaires
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
ZA202101362B (en) Compositions and methods for treating the eye
EP3634992A4 (fr) Procédés et compositions pour l'identification d'épitopes
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
EP3735457A4 (fr) Compositions et procédés pour produire des mégacaryocytes
MA53391A (fr) Compositions pour l'agriculture et procédés associés
EP3761970A4 (fr) Compositions et procédés pour le traitement de maladies neurologiques